Health Catalyst insider files Form 144 to sell 3,360 restricted shares via Morgan Stanley

Rhea-AI Filing Summary

Health Catalyst, Inc. (HCAT) reported a Form 144 notice showing a proposed sale of 3,360 common shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $11,298.67. The shares were acquired the same day as restricted stock issued by Health Catalyst as compensation. The filing lists 70,373,625 shares outstanding and indicates no securities sold by the reporting person in the past three months. The filer certifies no undisclosed material adverse information and provides standard Form 144 representations.

Insights

Securities Analyst

TL;DR Insider proposes to sell a small block of restricted shares acquired as compensation; size appears immaterial to capitalization.

The notice documents a proposed sale of 3,360 common shares valued at $11,298.67 executed via Morgan Stanley Smith Barney on 09/02/2025. These shares were acquired the same day as restricted stock issued by Health Catalyst and paid as compensation. Relative to the reported 70,373,625 shares outstanding, the block represents a negligible fraction of outstanding equity, suggesting limited market or governance impact. The filing confirms no sales in the prior three months and includes the standard attestation regarding material nonpublic information. From a compliance and disclosure perspective, the Form 144 appears routine and complete based on the provided fields.

Corporate Governance Specialist

TL;DR Routine disclosure of an insider sale tied to compensation; no red flags in the provided information.

The filing shows acquisition as restricted stock and subsequent proposed sale, a common sequence for awards subject to Rule 144 conditions. The inclusion of broker details and the attestation about material information align with regulatory expectations. Because the position size is minimal relative to total shares outstanding and there are no prior recent sales reported, this notice is unlikely to raise governance or signaling concerns based on the disclosed data alone.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	3360	11298.67	70373625	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Restricted Stock	Health Catalyst, Inc.			3360	09/02/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Health Catalyst's Form 144 for HCAT disclose?

The filing discloses a proposed sale of 3,360 common shares valued at $11,298.67 through Morgan Stanley Smith Barney on 09/02/2025.

How were the 3,360 HCAT shares acquired?

The shares were acquired on 09/02/2025 as restricted stock from Health Catalyst and the payment type is listed as compensation.

Does the Form 144 show recent sales by the reporting person?

No. The filing states Nothing to Report for securities sold during the past three months.

Who is the broker handling the proposed HCAT sale?

The broker is Morgan Stanley Smith Barney LLC located at 1 New York Plaza, 38th Floor, New York, NY, and the sale is to occur on the NASDAQ.

What portion of Health Catalyst's outstanding shares does this sale represent?

The filing reports 70,373,625 shares outstanding; 3,360 shares are a negligible fraction of that total based on the disclosed figures.